Drug Eluting Stents (DES)

23
Drug Eluting Stents (DES) by Carol Ongwenyi Mariam Israiel Rasha Ereifej

Transcript of Drug Eluting Stents (DES)

Page 1: Drug Eluting Stents (DES)

Drug Eluting Stents (DES)

by

Carol OngwenyiMariam IsraielRasha Ereifej

Page 2: Drug Eluting Stents (DES)

What is a Drug Eluting Stent? A drug-eluting stent (DES) is a coronary stent

(a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis. The stent is usually placed within the coronary artery by an Interventional Cardiologist during an angioplasty procedure.

Page 3: Drug Eluting Stents (DES)

DES and Bare Metal Stents Drug-eluting stents in current clinical use

were approved by the FDA after clinical trials showed they were statistically superior to bare-metal stents (BMS) for the treatment of native coronary artery narrowings, having lower rates of major adverse cardiac events (MACE) (usually defined as a composite clinical endpoint of death + myocardial infarction + repeat intervention because of restenosis)

Page 4: Drug Eluting Stents (DES)

Restenosis Historically, stents nonetheless remained vulnerable

to restenosis, caused almost exclusively by neointimal tissue growth. To address this issue, developers of drug-eluting stents used the devices themselves as a tool for delivering medication directly to the arterial wall. While initial efforts were unsuccessful, it was shown in 2001 that the release (elution) of drugs with certain specific physicochemical properties from the stent can achieve high concentrations of the drug locally, directly at the target lesion, with minimal systemic side effects. As currently used in clinical practice, "drug-eluting" stents refers to metal stents which elute a drug designed to limit the growth of neointimal scar tissue, thus reducing the likelihood of stent restenosis.

Page 5: Drug Eluting Stents (DES)

Drug Eluting Stents

Stents have 3 components: Stent Drug Delivery Vehicle Drug

Page 6: Drug Eluting Stents (DES)

Stent Manufacturing Companies

Cordis Boston ScientificAbbottConorGuidantMedtronicBiotronic

Page 7: Drug Eluting Stents (DES)

HistoryThe first successful trials were of sirolimus-eluting stents. A

clinical trial in 2002 led to approval of the sirolimus-eluting Cypher stent in Europe in 2002. After a larger pivotal trial (one designed for the purpose of achieving FDA approval), published in 2003, the device received FDA approval and was released in the U.S. in 2003. Soon thereafter, a series of trials of paclitaxel-eluting stents led to FDA approval of the Taxus stent in 2004.The Xience V everolimus eluting stent was approved by the FDA in July 2008 and has been available in Europe and other international markets since late 2006. It is an investigational device in Japan.

Stents quickly became the fastest-selling medical devices in recent history after their introduction in 2003. However, questions about the devices' safety compared with bare-metal stents slowed growth beginning in 2006.

Page 8: Drug Eluting Stents (DES)

A Brief History on StentingThe concept of the stent grew directly out of interventional

cardiologists' experience with angioplasty balloons in the first decade of use (1977-87).

Sometimes the wall of the coronary artery became weakened after balloon dilatation. Although the artery would be opened successfully using a balloon, in a small percentage of cases, the artery would collapse after the balloon was deflated -- sometimes this might not happen until the patient had been moved to the recovery room.

Since there was no interventional "fix" available, the only option for this patient was emergency bypass graft surgery to repair the problem.

Page 9: Drug Eluting Stents (DES)

The Challenges of Packaging Combination Devices & the Effect of Balloon Material Property on the Life of the Drug Eluting Coronary Stent (DECS) Structure

Page 10: Drug Eluting Stents (DES)

Packaging Combination DevicesPackaging Combination DevicesThe role of medical packaging is to

deliver a clean, sterile, protected medical device to the point of use and to allow aseptic presentation.

The package not only has to meet the needs of the stent, but also the needs of the drug incorporated into its polymer coating.

The package has to allow the transfer of ethylene oxide gas for sterilization, but when in storage, must provide a barrier to keep out moisture and oxygen.

Page 11: Drug Eluting Stents (DES)

Packing Combination DevicesPacking Combination Devices For combination products, the fundamentals of medical

packaging still apply, but there are new challenges facing the packaging designer involving not only protecting the device, but also maintaining the safety and effectiveness of the drug or biologic.

The designer must consider what affects there may be on the drug/biologic internal environment: + Biocompatibility+ Photostability+ Moisture sensitivity (hydrolysis)+ Reaction to gases (oxygen)

to prevent from Oxidation+ Temperature stability and its

effect on the safety and effectiveness of the drug product

Page 12: Drug Eluting Stents (DES)

DES Packing Protection & Stability TestingDES Packing Protection & Stability TestingThe packaging MUST be compatible with the

method of sterilization and should protect the device during handling, distribution and storage.

The purpose of stability testing is to provide evidence on how the quality of a drug product varies with time under the influence of a variety of environmental factors, to establish a retest period retest period for the drug substance, and/or a shelf lifeshelf life for the drug product and recommended storage conditionsrecommended storage conditions.

Page 13: Drug Eluting Stents (DES)

Study of Effect of Balloon and Stent-Balloon FrictionStudy of Effect of Balloon and Stent-Balloon FrictionThe presence of balloon in the

delivery system creates the partial loading of the stent.

Balloon used to deploy cardiovascular stent is actually folded inside the crimped stent before its deployment.

Stents are mounted over a balloon at the tip of the catheter before deployment.

Pressure is applied internally to inflate the balloon as well as the stent.

The balloon is removed and the stent is implanted in the vessel

How is the Coronary Stent Implanted?

Page 14: Drug Eluting Stents (DES)

Development of DES Packaging MaterialDevelopment of DES Packaging Material The foil material is a white multilayer structure consisting of

biaxially oriented polyamide, aluminum foil and a peelable sealant. DES packing employs TWO separate pouches:

+ Primary Sterile Pouch (nylon): - allows ethylene oxide sterilization (EtO) which has a porous membrane to allow gas flow during the sterilization cycle. + Secondary Non-sterile High Barrier Pouch (aluminum foil):

- have excellent barrier properties that protects the stent’s drug coating from oxygen and moisture during its packaged shelf life.

Packing Steps: + After sterilization, the primary pouch containing the DES is

placed inside the secondary pouch, which is gas flushed with a nonreactive gas such as nitrogen, and then sealed. To sequester any residual oxygen and moisture, a desiccant/oxygen scavenger may be used.

Aseptic Presentation & Easy Opening To allow easy access to the DES, the foil has a peelable sealant and

a “corner opening” feature is designed into the seal profile.

Seal Configuration

Opening Feature

Page 15: Drug Eluting Stents (DES)

Challenges: Risk Free SupplyChallenges: Risk Free SupplyApart from the obvious and serious

requirements that medical packaging should ensure absolute safety, there is also financial risk because of the high cost of the device. One DES costs approximately US$3000 compared with US$1000 for a bare metal stent.

It is estimated that in the sterilization

chamber there could be as much as US$10 million worth of stents. If for some reason the packaging fails, the DESs cannot be re-sterilizedDESs cannot be re-sterilized. It is therefore important that the pouch is produced using the highest possible “risk free” manufacturing standards.

Page 16: Drug Eluting Stents (DES)

Referenceshttp://www.mayoclinic.com/health/drug-eluting-

stents/HB00090http://www.americanheart.org/presenter.jhtml?

identifier=3043941http://www.devicelink.com/mddi/archive/

08/10/002.htmlhttp://www.ptca.org/news/2008/0702_XIENCEV.htmlhttp://www.persiabme.com/articles/view.asp?id=48

*****We all should have only one references slide…I just listed them so we can include them in our

final presentation

Page 17: Drug Eluting Stents (DES)

The Broad Medical Device Industry

MedicalDevice

Testing

Electronic Components

Metal Components

Biomedical Engineering

Plastics Components

Research

Packaging

Post-processing

Page 18: Drug Eluting Stents (DES)

Different Regulatory RequirementsCombination products present a difficult

regulatory challenge: which regulations should apply?

A separate Office of Combination Products (OCP) 2002

Page 19: Drug Eluting Stents (DES)

Packaging considerationsWhen packaging a ESD manufacturers must

consider:Regulatory mattersMaterialsMachinerySterilization methods

Page 20: Drug Eluting Stents (DES)

FDA ApprovalDeveloping and receiving FDA approval for a

DES is:

DifficultTime-consuming Expensive

Page 21: Drug Eluting Stents (DES)

Regulation Issues Medical device packager must comply with a whole

new set of packaging requirements and testing. Is the container and closure system suitable for use

with the drug? drug product packaging requirements involve batch-

to-batch uniformity of materials to ensure product safety and efficacy.

How is that drug going to interact with the materials used to make the stent?

Page 22: Drug Eluting Stents (DES)

Challenges Each device must be packaged to ensure that it is

functional and that pharmacological or biologic properties are protected until the point of use.

The ever-changing regulatory environment- It is difficult to predict the requirements of a global marketplace.

Would a new product offering be viewed as a device or a drug with the device serving as the delivery system?

This may lead to companies developing such combination products to have to deal with the regulations of both agencies, which could potentially lead to dual sets of requirements.

Page 23: Drug Eluting Stents (DES)

Opportunities Combining a medical device with a pharmaceutical

to create a drug delivery device is a great opportunity for both the device company and the pharmaceutical firm.